Patent · US Active

Factor VIII inhibitory antibodies with reduced glycosylation

US7785594B2 · kind B2 · utility

6Cited by
8References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 16, 2004
Grant dateAug 31, 2010
Priority date—
Expiry dateJun 27, 2026

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/70
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.